In a recent exclusive with Forbes, Dr. Amanda Hill, CEO of VitalBio, shared her vision for a future where healthcare is not just reactive—but deeply personalized, proactive, and data-driven.

VitalBio, a rising star in the biotech world, is pioneering next-generation diagnostics that enable real-time, at-home health monitoring. In the feature article, Dr. Hill discusses how her team is leveraging AI, genomics, and wearable technology to reshape how patients and providers interact with medical data.

Biotech Meets AI for Early Detection

At the center of VitalBio’s innovation is a proprietary bio-sensing platform capable of detecting biomarkers for chronic conditions such as diabetes, cardiovascular disease, and even early-stage cancers. The device integrates with a mobile app that delivers insights to both users and clinicians in real time.

Dr. Hill emphasized that early detection is only half the story. “Our system doesn't just alert—it guides,” she explained. “We use machine learning to suggest next steps, care plans, or follow-up screenings tailored to that individual’s medical history and risk profile.

Redefining Equity in Healthcare Access

Beyond the technology, the Forbes feature highlights Hill’s broader mission: using personalized healthcare as a tool for social impact.We’re not just innovating for the privileged," Hill stated. "We’ve partnered with community clinics and public health organizations to ensure our platform reaches underserved populations who need early detection the most.

Backed by Science, Powered by PRCOM

Since partnering with PRCOM, VitalBio has rapidly expanded its visibility, securing top-tier media coverage and investor interest. Dr. Hill credits the firm’s strategic media relations for shaping a compelling public narrative around science that often goes unseen.

What’s Next for VitalBio

The company is preparing for a Series C funding round and launching a multi-city pilot program with major health systems across the U.S. and Europe. Hill says the momentum is exciting—but the focus remains the same.